Eupraxia Pharmaceuticals Inc. (EPRX) vs Fate Therapeutics, Inc. (FATE)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Fate Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.74HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
FATE
Fate Therapeutics, Inc.
$2.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EPRX vs FATE
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)FATE -65.1% (-41.0%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX FATE
EPRX vs FATE: by the numbers
- •FATE is the larger company ($267M vs $259M market cap).
- •Both run net losses; EPRX's is the smaller (0.00% vs -1941.09% net margin).
Metrics side by side
Valuation
| Metric | EPRX | FATE |
|---|---|---|
| P/S ratio | N/A | 41.12 |
| P/B ratio | 2.55 | 1.74 |
Profitability
| Metric | EPRX | FATE |
|---|---|---|
| Gross margin | 0.00% | -94.12% |
| Operating margin | 0.00% | -2222.45% |
| Net margin | 0.00% | -1941.09% |
| ROE | -38.33% | -82.12% |
| ROIC | -43.56% | -58.72% |
Growth (annualized)
| Metric | EPRX | FATE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -32.98% |
| Total return CAGR (5Y) | N/A | -46.86% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.